



ASX Announcement

4th July 2023

Price Movement Clarification

SYDNEY, Australia, July 4th, 2023 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) refers to the increase in the price of AT1 shares from a closing price of \$0.036 on 3 July 2023 to a high of \$0.072 today.

Atomo advises that it is not aware of any information that has not been announced to the market which, if by known by some in the market, could explain the recent trading in its securities.

It is noted however that on 3 July 2023, Atomo's partner, Lumos Diagnostics (ASX: LDX) announced to the market that it has received US FDA approval for its FebriDx test, which utilises Atomo's user friendly integrated Pascal test platform, making Atomo a critical supplier to Lumos for this approved product. It is possible that the price movement in AT1 could be attributed to LDX's announcement.

Atomo confirms that it is in compliance with its continuous disclosure obligations under the ASX Listing Rules, and in particular, with ASX Listing Rule 3.1.

For more information, please contact:

John Kelly
Managing Director & CEO
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by the Managing Director & CEO, CFO, Company Secretary and Board Chair.

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.



Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, COVID-19, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnosics.com